Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-19 of 19

Sort by

Sort Order Select

Journal Articles

TP53 Mutations Distinguish a Class of Highly Homogenous Myeloid Neoplasms within MDS and AML in the Context of Complex Karyotype

Hongyan Tong, Ye Yang, Lingxu Jiang, Xinping Zhou, Liya Ma, Gaixiang Xu, Yudi Zhang, Wei Wang, Xiaozhen Liu, Huchu Yu

Blood (2024) 144 (Supplement 1): 6712.

https://doi.org/10.1182/blood-2024-207477

Published: 2024

Journal Articles

Orelabrutinib Combined with Bendamustine-Rituximab or Obinutuzumab Followed By Orelabrutinib Maintenance Therapy for Untreated Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study（Optimize Study）

Xuewu Zhang, Yanan Zhu, Xiang Zhang, Xingnong Ye, Gaixiang Xu, Liya Ma, Yanling Ren, Liping Mao, Min Yang, Chunmei Yang, Juying Wei, Yinjun Lou, Wenyuan Mai, Wanzhuo Xie, Haitao Meng, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6280.

https://doi.org/10.1182/blood-2024-204442

Published: 2024

Journal Articles

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Blood (2024) 144 (Supplement 1): 836.

https://doi.org/10.1182/blood-2024-208355

Published: 2024

Journal Articles

Decitabine Plus All- Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

Blood (2024) 144 (Supplement 1): 663.

https://doi.org/10.1182/blood-2024-200433

Published: 2024

Journal Articles

Construction and Evaluation of a Prognostic Model for Patients with Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 6144.

https://doi.org/10.1182/blood-2024-209459

Published: 2024

Journal Articles

Prognosis and Efficacy Analysis of Diffuse Large B-Cell Lymphoma with TP53 Mutations: A Single-Center Study

Haiyan Zhang, Xiang Zhang, Jinghan Wang, Xuewu Zhang, Yunfei Lv, Yanan Zhu, Juying Wei, Min Yang, Gaixiang Xu, Xingnong Ye, Yinjun Lou, Chunmei Yang, Haitao Meng, Wanzhuo Xie, Hongyan Tong, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6468.

https://doi.org/10.1182/blood-2024-205687

Published: 2024

Journal Articles

Practical Application of Orelabrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Analysis of Real-World Evidence (OCARE Study)

Xuewu Zhang, Haitao Meng, Gaixiang Xu, Min Yang, Wanzhuo Xie, Juying Wei, Liya Ma, Xingnong Ye, Liping Mao, Wenyuan Mai, Chunmei Yang, Yanling Ren, Hongyan Tong, Yanan Zhu, Xiang Zhang, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 6772.

https://doi.org/10.1182/blood-2024-203639

Published: 2024

Journal Articles

Safety and Efficacy of Selinexor Sequential Azacytidine in Newly Diagnosed Patients with Myelodysplastic Syndromes EB1 or EB2: A Single-Center, Single-Arm, Phase Ib/II Trial

Liya Ma, Wenli Yang, Xinping Zhou, Li Ye, Gaixiang Xu, Chao Hu, Yingwan Luo, Chunmei Yang, Zheng Ge, Hongyan Tong

Blood (2023) 142 (Supplement 1): 1856.

https://doi.org/10.1182/blood-2023-183101

Published: 2023

Journal Articles

Combination of Olverembatinib and VP Regimen As First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Gaixiang Xu, Yinjun Lou, Huafeng Wang, Wen-Juan Yu, Liping Mao, Jian Huang, Chenying Li, Shanshan Suo, Hongyan Tong, Jie Jin

Blood (2023) 142 (Supplement 1): 4205.

https://doi.org/10.1182/blood-2023-187130

Published: 2023

Journal Articles

Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

Nianci Chen, Jiajia Pan, Yile Zhou, Liping Mao, Yinjun Lou, Jiejing Qian, Gaixiang Xu, Juying Wei, De Zhou, Lihong Shou, Huang Li, Minchao Yan, Hui Zeng, Cuihua Fan, Gongqiang Wu, Weiying Feng, Hongyan Tong, Jie Jin, Huafeng Wang

Blood (2023) 142 (Supplement 1): 5926.

https://doi.org/10.1182/blood-2023-182806

Published: 2023

Journal Articles

Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of the EB Subtype of Primary Myelodysplastic Syndrome Patients with Myelofibrosis

Gaixiang Xu, Wei Wang, Shuanghong Zhu, Kongfei Li, Xinping Zhou, Liya Ma, Li Ye, Chen Mei, Lu Wang, Lingxu Jiang, Haitao Meng, Wen-Juan Yu, Jie Jin, Hongyan Tong, Jian Huang

Blood (2023) 142 (Supplement 1): 6481.

https://doi.org/10.1182/blood-2023-184789

Published: 2023

Journal Articles

High Expressions of Checkpoint Receptors in T Cells Subsets of Myelodysplastic Syndromes Patients with TP53 Mutations

Lingxu Jiang, Xin Huang, Xinping Zhou, Li Ye, Lu Wang, Chen Mei, Liya Ma, Gaixiang Xu, Chao Hu, Ziyang Zhou, Xiaozhen Liu, Yueyuan Han, Zheng Ge, Hongyan Tong

Blood (2023) 142 (Supplement 1): 4614.

https://doi.org/10.1182/blood-2023-182601

Published: 2023

Journal Articles

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

Blood (2023) 142 (Supplement 1): 5384.

https://doi.org/10.1182/blood-2023-184470

Published: 2023

Journal Articles

How Induction Cycles before Remission Influence Long-Term Survival in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 6001.

https://doi.org/10.1182/blood-2023-186048

Published: 2023

Journal Articles

Olverembatinib Plus Low-Intensive Regimen in Frontline Therapy for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia： a Case Series from a Single Center

Yinjun Lou, Gaixiang Xu, Huafeng Wang, Liping Mao, Hongyan Tong, Jie Jin

Blood (2022) 140 (Supplement 1): 11683–11684.

https://doi.org/10.1182/blood-2022-165879

Published: 2022

Journal Articles

The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway

Lingxu Jiang, Xinping Zhou, Chao Hu, Chen Mei, Gaixiang Xu, Liya Ma, Yanling Ren, Li Ye, Lu Wang, Yingwan Luo, Jie Jin, Jie Sun, Hongyan Tong

Blood (2022) 140 (Supplement 1): 6894–6895.

https://doi.org/10.1182/blood-2022-165203

Published: 2022

Journal Articles

EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes

Qi Zhang, Wei Lang, Lu Wang, Wenli Yang, Yingwan Luo, Shuanghong Zhu, Lingxu Jiang, Yuxia Wang, Chen Mei, Xinping Zhou, Yanling Ren, Liya Ma, Li Ye, Xingnong Ye, Gaixiang Xu, Jie Sun, Jie Jin, Hongyan Tong

Blood (2022) 140 (Supplement 1): 9767–9768.

https://doi.org/10.1182/blood-2022-165886

Published: 2022

Journal Articles

Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of Primary Myelodysplastic Syndrome Patients with Myelofibrosis

Gaixiang Xu, Shuanghong Zhu, Xinping Zhou, Kongfei Li, Lingxu Jiang, Hongyan Tong, Jie Jin

Blood (2022) 140 (Supplement 1): 9796–9797.

https://doi.org/10.1182/blood-2022-165344

Published: 2022

Journal Articles

Venetoclax Combined with Daunorubicin and Cytarabine (DAV) As Induction Therapy in De Novo Young Adult Acute Myeloid Leukemia

Huafeng Wang, Liping Mao, Wanzhuo Xie, Hongyan Tong, Min Yang, Gaixiang Xu, Xiujin Ye, Ying Lu, Juying Wei, Wenyuan Mai, De Zhou, Jie Jin, Hong-Hu Zhu

Blood (2021) 138 (Supplement 1): 2334.

https://doi.org/10.1182/blood-2021-153257

Published: 2021

NARROW

TP53 Mutations Distinguish a Class of Highly Homogenous Myeloid Neoplasms within MDS and AML in the Context of Complex Karyotype

Orelabrutinib Combined with Bendamustine-Rituximab or Obinutuzumab Followed By Orelabrutinib Maintenance Therapy for Untreated Marginal Zone Lymphoma (MZL): A Prospective ,Multicenter, Clinical Study（Optimize Study）

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Decitabine Plus All- Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

Construction and Evaluation of a Prognostic Model for Patients with Acute Myeloid Leukemia

Prognosis and Efficacy Analysis of Diffuse Large B-Cell Lymphoma with TP53 Mutations: A Single-Center Study

Practical Application of Orelabrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Analysis of Real-World Evidence (OCARE Study)

Safety and Efficacy of Selinexor Sequential Azacytidine in Newly Diagnosed Patients with Myelodysplastic Syndromes EB1 or EB2: A Single-Center, Single-Arm, Phase Ib/II Trial

Combination of Olverembatinib and VP Regimen As First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia

Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of the EB Subtype of Primary Myelodysplastic Syndrome Patients with Myelofibrosis

High Expressions of Checkpoint Receptors in T Cells Subsets of Myelodysplastic Syndromes Patients with TP53 Mutations

Risk Factors for Severe Infection and Unfavorable Outcomes in Hematologic Malignancy Patients with COVID-19 Inflection during the Omicron Era: A Chinese Single-Center Retrospective Study

How Induction Cycles before Remission Influence Long-Term Survival in Acute Myeloid Leukemia

Olverembatinib Plus Low-Intensive Regimen in Frontline Therapy for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia： a Case Series from a Single Center

The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway

EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes

Analysis of Clinical Features, Prognostic Characteristics and Gene Mutations of Primary Myelodysplastic Syndrome Patients with Myelofibrosis

Venetoclax Combined with Daunorubicin and Cytarabine (DAV) As Induction Therapy in De Novo Young Adult Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only